Orthocell Limited (ASX: 0CC) reported record quarterly revenue of AU$1.84 million and year-on-year growth of 30% to AU$6.72 million. They have a strong balance sheet with AU$20.60 million cash at the bank. Orthocell is launching a third revenue-generating product, SmrtGraft™ for tendon repair, and achieved compelling success rates with their Remplir™ nerve repair and Striate+™ dental implant products. They also expect top-line results from Remplir™ US market authorization study in Q4 CY24.
Orthocell recorded cash receipts of AU$9,76,000 from customers for the quarter, with a net cash inflow of AU$7,90,000 from operating activities. The company maintained a cash balance, enabling its expansion strategy into the USA in 2025 and international regulatory applications. The growth in revenue from the Australian market, particularly from Remplir, underlines the substantial revenue opportunities in global markets.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 21, 2024
Nov 20, 2024
Nov 20, 2024
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
